- Home
- AVXL vs TTGT Comparison
AVXL vs TTGT Comparison
Compare AVXL & TTGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVXL
- TTGT
- Stock Information
- Founded
- AVXL 2004
- TTGT 1999
- Country
- AVXL United States
- TTGT United States
- Employees
- AVXL N/A
- TTGT N/A
- Industry
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- TTGT Telecommunications Equipment
- Sector
- AVXL Health Care
- TTGT Telecommunications
- Exchange
- AVXL Nasdaq
- TTGT Nasdaq
- Market Cap
- AVXL 710.3M
- TTGT 598.8M
- IPO Year
- AVXL N/A
- TTGT 2007
- Fundamental
- Price
- AVXL $9.09
- TTGT $6.82
- Analyst Decision
- AVXL Strong Buy
- TTGT Buy
- Analyst Count
- AVXL 2
- TTGT 6
- Target Price
- AVXL $44.00
- TTGT $19.33
- AVG Volume (30 Days)
- AVXL 825.3K
- TTGT 512.6K
- Earning Date
- AVXL 08-05-2025
- TTGT 08-07-2025
- Dividend Yield
- AVXL N/A
- TTGT N/A
- EPS Growth
- AVXL N/A
- TTGT N/A
- EPS
- AVXL N/A
- TTGT N/A
- Revenue
- AVXL N/A
- TTGT $284,897,000.00
- Revenue This Year
- AVXL N/A
- TTGT $79.55
- Revenue Next Year
- AVXL N/A
- TTGT N/A
- P/E Ratio
- AVXL N/A
- TTGT N/A
- Revenue Growth
- AVXL N/A
- TTGT 13.01
- 52 Week Low
- AVXL $3.76
- TTGT $6.51
- 52 Week High
- AVXL $14.44
- TTGT $33.08
- Technical
- Relative Strength Index (RSI)
- AVXL 64.24
- TTGT 40.38
- Support Level
- AVXL $7.97
- TTGT $6.51
- Resistance Level
- AVXL $9.35
- TTGT $7.26
- Average True Range (ATR)
- AVXL 0.38
- TTGT 0.70
- MACD
- AVXL 0.18
- TTGT -0.02
- Stochastic Oscillator
- AVXL 86.10
- TTGT 13.54
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.